BriaCell Reports 71% Central Nervous System Response Rate In Advanced Breast Cancer Patients With Central Nervous System Metastases Support Clinical Efficacy Of Bria-IMT, Alone And In Combination With An Immune Checkpoint Inhibitor

BriaCell Therapeutics Corp Ordinary Shares -6.83% Pre

BriaCell Therapeutics Corp Ordinary Shares

BCTX

2.32

2.32

-6.83%

0.00% Pre

  • 71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune checkpoint inhibitor (CPI)

     
  • Tumor reductions observed in heavily pretreated patients highlight potential clinical benefit of Bria-IMT™ in managing CNS metastases

PHILADELPHIA and VANCOUVER, British Columbia, Dec. 28, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report marked 71% intracranial objective response rate (iORR) in advanced breast cancer patients suffering from central nervous system (CNS) metastases and treated with BriaCell's Bria-IMT™ regimen. iORR is defined as the percentage of patients who achieve either a complete response (complete disappearance) or partial response (volume reduction of 30% or more) in intracranial tumors.

Breast cancer metastasis (spread of the cancer) to the CNS presents a significant clinical challenge, often leading to poor prognosis and early death. BriaCell has recently conducted a retrospective analysis in breast cancer patients with CNS metastases enrolled across both its Bria-IMT™ monotherapy and combination therapy with CPI studies and found remarkable clinical responses.

"We have accumulated positive clinical responses in five patients with intracranial metastases, which generally are extremely difficult to treat, and have a very poor prognosis. This antitumor activity furthers our excitement in our ongoing Phase 3 pivotal trial studying the Bria-IMT™ regimen in advanced breast cancer," stated Dr. William V. Williams, BriaCell's President and CEO.

"The CNS tumor reductions demonstrated in five of seven advanced breast cancer patients are particularly compelling given the history of unsuccessful treatment of CNS metastases in this patient population," stated Dr. Giuseppe Del Priore, BriaCell's Chief Medical Officer.

BriaCell Clinical Data in Advanced Metastatic Breast Cancer Patients with CNS Metastases

The Bria-IMT™ Regimen (Alone or Combined with a CPI)

  • CNS lesions improved in 71% of patients (5 of 7), supporting clinical efficacy of the Bria-IMT™ regimen
  • Findings provide evidence for the efficacy of the Bria-IMT™ regimen, both alone and in combination with CPI, in CNS metastases patients
  • Heavily pretreated metastatic breast cancer patients had failed multiple prior treatments including one patient who had failed treatments with 2 antibody-drug conjugates
  • Regression of CNS metastatic tumors was observed across all breast cancer subtypes in heavily pretreated patients highlighting the potential of the Bria-IMT™ regimen in managing CNS metastases

BriaCell is adding a pre-planned subgroup analysis of patients with CNS metastases to its pivotal Phase 3 study in advanced metastatic breast cancer patients. This could provide an additional indication for market approval of Bria-IMT™.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via